Programmed cell death protein-1 (PD-1) and PD-Ligand (L) -1 have been the focus of several clinical investigations owing to their roles in the tumor microenvironment and as predictors of response to immune checkpoint inhibitors (ICI).(7). Here, PDCD1 is linked to neoplasm.